Videos de Experimentos Relacionados
El programa CHARM es el programa
Lancet (London, England)
|November 25, 2003
Resumen
No abstract available in PubMed .
Videos de Conceptos Relacionados
También podría leer
Artículos Relacionados
Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.
Ordenar por
Same author
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
JACC. Heart failure·2021
Same author
The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure.
Journal of cardiac failure·2021
Same author
Relationship between a single measurement at baseline of body mass index, glycated hemoglobin, and the risk of mortality and cardiovascular morbidity in type 2 diabetes mellitus.
Cardiovascular endocrinology & metabolism·2020
Same author
Myocardial remodelling after withdrawing therapy for heart failure in patients with recovered dilated cardiomyopathy: insights from TRED-HF.
European journal of heart failure·2020
Same author
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
European heart journal·2020
Same journal
Assisted dying and the silencing of medicine's next generation.
Lancet (London, England)·2026
Same journal
Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.
Lancet (London, England)·2026
Same journal
Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.
Lancet (London, England)·2026
Same journal
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
Lancet (London, England)·2026
Same journal
Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.
Lancet (London, England)·2026